LivaNova (NASDAQ:LIVN) Price Target Lowered to $64.00 at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its price target lowered by stock analysts at Needham & Company LLC from $75.00 to $64.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 56.36% from the stock’s previous close.

LIVN has been the topic of several other research reports. Mizuho decreased their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Finally, Robert W. Baird boosted their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $64.20.

LivaNova Stock Down 1.3 %

Shares of LIVN opened at $40.93 on Wednesday. The firm has a market cap of $2.22 billion, a P/E ratio of 97.45 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a 52 week low of $40.37 and a 52 week high of $64.47. The firm’s 50-day simple moving average is $47.52 and its 200 day simple moving average is $49.50.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Several institutional investors and hedge funds have recently bought and sold shares of LIVN. Vanguard Group Inc. raised its position in shares of LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after buying an additional 265,291 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after acquiring an additional 806,374 shares in the last quarter. Capital Research Global Investors increased its stake in LivaNova by 19.1% in the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock valued at $74,690,000 after acquiring an additional 258,730 shares during the last quarter. Geode Capital Management LLC raised its position in LivaNova by 0.6% during the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after purchasing an additional 8,331 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in LivaNova by 8.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock worth $60,710,000 after purchasing an additional 107,693 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.